Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VOR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVor Biopharma appoints Dr. David Zaccardelli to Board following director resignation
Filed July 7, 2026 · Period ending July 6, 2026 · ~1 min read
Key Changes
-
medium
Dr. David Zaccardelli appointed as independent Class II director, bringing experience as former CEO of Verona Pharma (acquired by Merck 2025) and Dova Pharmaceuticals (acquired by Sobi 2019).
Item 5.02 verify on EDGAR → -
low
Dr. Andrew Levin resigned from the Board effective July 6, 2026, with the filing stating the resignation was not due to any disagreement with the Company.
Item 5.02 verify on EDGAR → -
low
Dr. Zaccardelli will receive standard non-employee director compensation: $40,000 annual cash retainer and initial stock options for up to 68,000 shares or $700,000 fair value.
Item 5.02 verify on EDGAR →
Summary
Vor Biopharma disclosed a routine Board transition on July 6-7, 2026. Dr. Andrew Levin resigned from the Board, and the Company immediately filled the vacancy by appointing Dr. David Zaccardelli as an independent Class II director. The filing explicitly states Dr. Levin's departure was not due to any disagreement with the Company, indicating an amicable separation. Dr.
Zaccardelli brings relevant pharmaceutical industry leadership experience, having previously served as CEO of Verona Pharma (acquired by Merck in 2025) and Dova Pharmaceuticals (acquired by Sobi in 2019). He will serve until the 2029 annual meeting and receive standard non-employee director compensation under the Company's existing policy. This is a routine governance matter with no material impact on operations or strategy.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Board member Dr. Andrew Levin resigned; Dr. David Zaccardelli appointed as independent Class II director to fill the vacancy.
Added in current filing · verify on EDGAR →
On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.
Dr. David Zaccardelli was appointed to fill the Board vacancy as an independent Class II director. He will serve until the 2029 annual meeting. Dr. Zaccardelli brings significant pharmaceutical industry experience, having served as CEO of multiple public pharmaceutical companies including Verona Pharma (acquired by Merck in 2025) and Dova Pharmaceuticals (acquired by Sobi in 2019).
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Pursuant to the Non-Employee Directors’ Compensation Policy, Dr. Zaccardelli will receive an annual cash retainer fee of $40,000 for service as a director, payable in equal quarterly installments in arrears on the last day of each fiscal quarter, pro-rated based on the number of days served in the applicable fiscal quarter. In addition, Dr. Zaccardelli will receive an initial grant of stock options to purchase the lesser of (i) 68,000 shares of the Company’s common stock and (ii) a number of shares of the Company’s common stock with an aggregate grant date fair value equal to $700,000 in connection with his appointment as a director and will be eligible to receive an annual stock option grant to purchase the lesser of (i) 34,000 shares of the Company’s common stock and (ii) a number of shares of the Company's common stock with an aggregate grant date fair value equal to $350,000 on the date of each annual stockholder meeting of the Company, beginning with the 2027 annual stockholder meeting.
Dr. Zaccardelli will receive standard non-employee director compensation: $40,000 annual cash retainer paid quarterly, an initial stock option grant for up to 68,000 shares or $700,000 fair value (whichever is less), and annual option grants for up to 34,000 shares or $350,000 fair value starting in 2027. This follows the Company's standard compensation policy for non-employee directors.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify